The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic of Covid-19 vaccine and the need of vaccination has often been mentioned in the media. Even so, new vaccines are still being developed all around the world. They play a key role in treatment of the infected and pharmaceutical companies are fighting for development of the most effective drug. OZIOS has prepared a summary to introduce how companies are doing on the market.
Your retention will contact you in a few minutes with more information about this trading strategy.
U.S. companies seized the opportunity to develop Covid-19 vaccine
Gilead Sciences and its Remdesivir
Treatment with Remdesivir has been provided to roughly half of all hospitalized Covid-19 patients in the United States. Even though opinions of scientists on Remdesivir differ, it became the only fully approved drug against Covid-19. Research performed by Market Research Future estimated that the market will reach roughly USD 10,119.99 million till 2027 thanks to the drug developed by Gilead Sciences. In connection with this particular drug, companies such as Mylan, Cipla, Hetero Labs and Jubilant Life Sciences should be mentioned. Gilead Sciences (GILD) became an important part of the healthcare sector including companies such as Amgen Inc. (AMGN) and Johnson & Johnson (JNJ). Current earnings per share of the company rose to 4.1 %. According to Zacks Investment Research, expected profit growth will be 0.81 % in 2021, compared to an industry average of 7.7 %.
Gilead Sciences' performance during last five years. Source: www.investing.com
Eli Lilly and Company and its Bamlanivimab and Etesevimab
The company has newly received authorization of emergency use authorization for bamlanivimab and etesevimab, administered together, to include emergency use as post-exposure prophylaxis for Covid-19. The emergency use is applicable to patients exposed to an individual infected with the SARS-CoV-2 virus or patients who are at high risk of hospitalization. The authorization enables treatment of high-risk patients over 12 years who are not fully vaccinated or who are not expected to mount an adequate immune response to complete vaccination, or have been exposed to an individual infected with SARS-CoV-2, or those who are at high risk of exposure to an individual infected with Covid-19, including the elderly and prisoners. In 2020, Eli Lilly and Company reported total revenues of USD 24.5 billion. The pharmaceutical company recently announced its Q2 results – its revenues exceed, but profits are far from estimates. The year-on-year increase was roughly 23 % and a total revenue rose to $ 6.7 billion.
Performance of Eli Lilly and Company during last 5 years. Source: www.investing.com
Regeneron Pharmaceuticals and its REGEN-COV (casirivimab and imdevimab)
The biotechnology company develops and manufactures drugs for the treatment of serious diseases. The pharmaceutical company is well-known for its Covid-19 drug containing casirivimab and imdevimab. Nowadays, REGEN-COV can be used as a treatment to infected patients in order to reduce the risk of hospitalization or death from Covid-19, and post-exposure prophylaxis for close contact with infected persons. Recently, the company announced an agreement on 1.4 million doses of REGEN-COV with the U.S. government. The vaccines should be ready by the end of January 2022. The cost of approximately USD 2,100 per dose represents roughly USD 2.9 billion in total. Regeneron Pharmaceuticals stocks have risen to 35% during 2021.*
Performance of Regeneron during last 5 years. Source: www.investing.com
Other companies developing Covid-19 drugs
Other important companies developing drugs against the deadly virus are:
· Grifols - global specialized pharmaceutical company based in Spain developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The company develops 7 products against Covid-19 and uses convalescent plasma from recovered Covid-19 donors for direct transfusion.
· Johnson & Johnson
· Tonix Pharmaceuticals
· Novartis
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 0% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Legal information: O.Z.I. Online Zone Investment Opportunities (OZIOS) is a registered brand name of APME FX Trading Europe Ltd, a Cyprus Investment Firm regulated by the Cyprus Securities and Exchange Commission (CySEC) with License No 335/17. The company's registered office address is 21 Kyriakou Oikonomou, 3040, Limassol, Cyprus.
* Past performance is no guarantee of future results.
* Past performance is no guarantee of future results.
* Past performance is no guarantee of future results.
* Past performance is no guarantee of future results.
Αποποίηση ευθυνών
Το υλικό του παρόντος θεωρείται επικοινωνία μάρκετινγκ σύμφωνα με τους σχετικούς νόμους και κανονισμούς και ως εκ τούτου δεν αποτελεί αντικείμενο της απαγόρευσης της συναλλαγής πριν από τη διάδοση της έρευνας των επενδύσεων. Δεν έχει προετοιμαστεί σύμφωνα με τις νομικές απαιτήσεις που αποσκοπούν στην προώθηση της ανεξαρτησίας της έρευνας των επενδύσεων και δεν πρέπει να ερμηνεύονται ότι περιέχουν επενδυτικές συμβουλές ή μια σύσταση επενδύσεων ή προσφορά ή πρόσκληση για οποιεσδήποτε συναλλαγές σε χρηματοπιστωτικά μέσα. Το δημοσιευμένο περιεχόμενο προορίζεται μόνο για εκπαιδευτικούς/ενημερωτικούς σκοπούς. Δεν λαμβάνει υπόψη την οικονομική κατάσταση, την προσωπική εμπειρία ή τους επενδυτικούς στόχους των αναγνωστών. Η APME FX Trading Europe Ltd δεν εκπροσωπεί ότι οι παρεχόμενες πληροφορίες είναι ακριβείς, τρέχουσες ή πλήρεις. και ως εκ τούτου, δεν αναλαμβάνει καμία ευθύνη για τυχόν ζημίες που προκύπτουν από επενδύσεις με βάση το παρεχόμενο περιεχόμενο. Η προηγούμενη απόδοση δεν αποτελεί εγγύηση μελλοντικών αποτελεσμάτων.
Η εταιρεία κατασκευής τσιπ TSMC θα αποκτήσει δισεκατομμύρια για να επεκτείνει τις δραστηριότητές της
The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic...
Έρχονται τα εμβόλια νέας γενιάς από τη Moderna
The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic...
Η Cisco Systems επεκτείνει τα εργαλεία επικοινωνίας της και επενδύει στην τεχνητή νοημοσύνη δεδομένων
The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic...
Είμαστε διαθέσιμοι και στο +357 25 054 734
Προειδοποίηση κινδύνου: Τα CFD είναι πολύπλοκα μέσα και συνοδεύονται από υψηλό κίνδυνο ταχείας απώλειας χρημάτων λόγω μόχλευσης. 86,61% των λογαριασμών ιδιωτών επενδυτών χάνουν χρήματα κατά τη διαπραγμάτευση CFD με αυτόν τον πάροχο. Θα πρέπει να εξετάσετε εάν καταλαβαίνετε πώς λειτουργούν τα CFD και εάν έχετε την οικονομική δυνατότητα να αναλάβετε τον υψηλό κίνδυνο να χάσετε τα χρήματά σας. Διαβάστε τις Γνωστοποίηση Κινδύνου.